Optimal Use of Sandimmun® in Nephrotic Syndrome

Since 1978, when Sandimmun was first used in humans, great
experience has been gathered in clinical transplantation by
the treatment of about half a million patients.
The experience with Sandimmun in nephrotic syndrome is put
into perspective and compared with alternatives such as
corticosteroids and cytotoxic agents. Sandimmun may be
regarded as a leap forward in the treatment of that
population of patients that do not satisfactorily respond to
steroids. The possibility of drastically reducing the use of
corticosteroids, particularly in children, is perhaps the
most attractive feature of Sandimmun.
This book gives the results ofa worldwide clinical
programme. It includes authors' personal experience as well
as an analysis of all data made available. A careful
assessment of reported side effects is also given.